Marshall Wace’s Traws Pharma TRAW Stock Holding History

Marshall Wace’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-974	Closed	-$169K	–	3502
2021 Q2	$169K	Buy	+974	New	+$220K	﹤0.01%	2479

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's TRAW Position: Q3 2021 in Review

Marshall Wace sold out of Traws Pharma (TRAW) in Q3 2021, closing a stake of 974 shares — an estimated $169K sold.

Marshall Wace first reported a position in TRAW in Q2 2021 and held it in 1 quarter. The position peaked at $169K in Q2 2021. 34 funds tracked by Wall St. Rank hold TRAW as of Q3 2021.

Marshall Wace reported no remaining Traws Pharma position as of Q3 2021 after selling out during the quarter.
Marshall Wace sold 974 Traws Pharma shares in Q3 2021, an estimated $169K.
Marshall Wace first reported a position in Traws Pharma in Q2 2021 and held it in 1 quarter.
Marshall Wace's Traws Pharma position peaked at $169K in Q2 2021.
34 funds tracked by Wall St. Rank held Traws Pharma as of Q3 2021.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.